Overview

Detailed Summary

Hindustan Bio Science Ltd is primarily engaged in manufacturing and selling pharmaceutical products, specifically in pharmaceuticals and biotechnology sectors.
The company has a diverse operational scope, transitioning from bulk drug sourcing to manufacturing finished dosage forms of pharmaceuticals.
Hindustan Bio Science holds DCGI approval for marketing the nephrology product 'Recombinant Human Erythropoietin', branded as 'EPOVIN'.
The company boasts world-class facilities for a range of pharmaceutical production, trusted globally by healthcare professionals and patients.
Originally involved in the cement industry, the firm has undergone several transformations, reflecting strategic diversification into biotech and pharmaceuticals.

Sector: IT - Software
Industry: Software Products
Market Cap: 7 Cr
Volatility: Low Risk
P/E Ratio: 0.0
Industry P/E: 17.4
PEG Ratio: —
P/B Ratio: 8.9
52W High: 9.92
52W Low: 5.00

Sales CAGR

1Y: -22.86%
3Y: 23.61%
5Y: -15.99%
10Y: -4.75%

Profit CAGR

1Y: 66.67%
3Y: —
5Y: 4.48%
10Y: —

ROE

TTM: -9.55%
3Y: 4.80%
5Y: -29.46%
10Y: -29.78%

ROCE

TTM: -2.46%
3Y: 1.42%
5Y: -10.65%
10Y: -17.34%

Technicals

‌

Forecasts

Peers

Information Technology Information Technology IT - Software Software Products

Symbol	Watchlist	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
HITKITGLO		1.80	10 Cr	90.00	0.75	0.00	0.70	0.68	0.68
SVAMSOF		5.50	9 Cr	110.00	0.48	0.00	0.47	2.32	0.39
HINDBIO		7.20	7 Cr	—	8.89	0.00	-9.55	-2.46	-2.81
FIRSTFIN		6.94	7 Cr	—	0.69	0.00	-0.51	0.14	-0.48
NIHARINF		5.99	6 Cr	9.08	0.93	0.00	10.22	9.69	3.28
OMNIAX		3.01	5 Cr	—	0.45	0.00	-0.48	-0.48	-0.51
VIRGOGLOB		4.26	4 Cr	—	7.83	0.00	-40.48	-40.44	-2.85
Median: 7 Co.	—	5.50	7 Cr	90.00	0.75	0.00	-0.48	0.14	-0.48

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Standalone Quarterly Results (in ₹ Crores)

Total Figures

QoQ Changes

Total Figures

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales	0.32	0.39	0.41	0.00	0.00	0.38	0.32	0.00	0.38	0.00
Expenses	0.27	0.35	0.34	0.05	0.04	0.28	0.32	0.07	0.31	0.12
Operating Profit	0.05	0.04	0.07	-0.05	-0.04	0.10	0.00	-0.07	0.07	-0.12
OPM %	15.63	10.26	17.07	—	—	26.32	0.00	—	18.42	—
Other Income	0.01	0.00	0.01	0.00	0.00	0.01	0.01	0.01	0.02	0.00
Interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00
Profit Before Tax	0.07	0.04	0.08	-0.05	-0.04	0.11	0.01	-0.06	0.08	-0.12
Tax %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit	0.07	0.04	0.08	-0.05	-0.04	0.11	0.01	-0.06	0.08	-0.12
EPS in Rs	0.07	0.04	0.08	-0.05	-0.04	0.11	0.01	-0.06	0.08	-0.11

Standalone Profit Loss (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Sales	1.01	1.03	3.56	1.94	1.03	0.43	0.92	1.05	0.81	0.70
Expenses	1.48	3.38	3.43	1.81	1.97	0.94	0.95	0.99	0.71	0.69
Operating Profit	-0.47	-2.35	0.13	0.14	-0.94	-0.51	-0.03	0.06	0.10	0.01
OPM %	-46.00	-227.91	3.73	7.00	-91.13	-117.53	-3.06	6.07	12.27	1.43
Other Income	0.00	0.09	0.00	0.00	0.00	0.00	0.00	0.00	0.00	NaN
Interest	0.01	0.00	0.01	0.01	0.01	0.00	0.00	0.00	0.00	0.00
Depreciation	0.01	0.01	0.01	0.01	0.01	0.00	0.01	0.01	0.00	0.00
Profit Before Tax	-0.49	-2.27	0.11	0.12	-0.96	-0.51	-0.04	0.05	0.10	0.03
Tax %	-0.86	-0.18	2.09	30.56	1.62	-0.59	-6.60	-7.97	-2.55	0.00
Net Profit	-0.49	-2.28	0.11	0.08	-0.94	-0.52	-0.04	0.06	0.10	0.03
EPS in Rs	-0.49	-2.22	0.10	0.08	-0.91	-0.50	-0.03	0.05	0.10	-0.08
Dividend Payout %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—

Standalone Balance Sheet (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	10	10	10	10	10	10	10	2.05	2.05	2.05
Reserves	-5.43	-5.92	-8.20	-8.09	-8.01	-8.95	-9.46	-1.30	-1.25	-1.15
Borrowings	0.94	1.30	1.57	3.37	2.60	1.86	2.17	2.46	2.56	2.51
Other Liabilities	0.12	0.25	0.09	0.10	0.72	0.32	0.02	0.08	0.01	0.01
Total Liabilities	5.88	5.87	3.71	5.63	5.56	3.49	2.98	3.29	3.37	3.42
Fixed Assets	0.07	0.06	0.06	0.06	0.05	0.04	0.04	0.03	0.03	0.03
CWIP	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Assets	5.81	5.81	3.65	5.57	5.51	3.45	2.94	3.25	3.35	3.40
Total Assets	5.88	5.87	3.71	5.63	5.56	3.49	2.98	3.29	3.37	3.42

Standalone Cash Flows (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	0.46	-0.16	-0.23	-1.32	0.82	0.75	-0.34	-0.05	-1.41	0.03
Cash from Investing Activity	-0.00	-0.00	-0.00	-0.01	0.00	0.00	-0.00	0.00	0.00	0.00
Cash from Financing Activity	-0.63	0.18	0.21	1.50	-0.81	-0.93	0.34	0.05	1.43	-0.05
Net Cash Flow	-0.17	0.01	-0.02	0.17	0.01	-0.18	-0.01	0.00	0.03	-0.02

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	12.19%	12.19%	12.19%	12.19%	12.19%	12.19%	12.19%	12.19%	12.19%	12.19%	12.19%	12.19%
FIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
DIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Public	87.81%	87.81%	87.81%	87.81%	87.81%	87.81%	87.81%	87.81%	87.81%	87.81%	87.81%	87.81%
Total Shareholders	9,253	10,315	10,921	11,779	11,618	11,276	11,246	11,620	11,405	11,516	11,530	11,707

Market Transactions

Unlock more with professional

Real-time bulk & block deal transactions
Export transaction data for analysis

Projection

Documents

Presentations

Concalls

Reports

Presentations

No documents found!

Actions

Action Type

‌
‌

Announcements

Last 7 days

Sentiment

Board Meeting

4 days ago

Hindustan Bio Sciences Board Meeting 31 July 2026

Hindustan Bio Sciences Ltd: Board meeting scheduled on 2026-07-31 at registered office to consider unaudited financial results for quarter ended 30.06.2026 and other matters.

Board Meeting

4 days ago

Hindustan Bio Sciences Board Meeting on 2026-07-31

Hindustan Bio Sciences Ltd notified BSE that its Board will meet on 2026-07-31 at the registered office to consider unaudited financial results for the quarter ended 30-06-2026 and other matters.

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

Ask AI

Frequently Asked Questions about Hindustan Bio Sciences Ltd

Hindustan Bio Sciences Ltd (HINDBIO) is currently trading at 7.20 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Hindustan Bio Science Ltd is primarily engaged in manufacturing and selling pharmaceutical products, specifically in pharmaceuticals and biotechnology sectors. The company has a diverse operational scope, transitioning from bulk drug sourcing to manufacturing finished dosage forms of pharmaceuticals. Hindustan Bio Science holds DCGI approval for marketing the nephrology product 'Recombinant Human Erythropoietin', branded as 'EPOVIN'. The company boasts world-class facilities for a range of pharmaceutical production, trusted globally by healthcare professionals and patients. Originally involved in the cement industry, the firm has undergone several transformations, reflecting strategic diversification into biotech and pharmaceuticals.

Over the past 52 weeks, Hindustan Bio Sciences Ltd has traded between a low of ₹5.00 and a high of ₹9.92. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Hindustan Bio Sciences Ltd has a market capitalization of approximately 7.38. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Hindustan Bio Sciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of N/A and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 7.38 Cr, Hindustan Bio Sciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Hindustan Bio Sciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Hindustan Bio Sciences Ltd is N/A. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Hindustan Bio Sciences Ltd

Stock Summary and Key Metrics

Investment Checklist

Investment Checklist

Overview

Financial Ratios

Technicals

Forecasts

Peers

Price Chart Comparison